Literature DB >> 911575

Evidence of a role for the peripheral chemoreceptors in the ventilatory response to doxapram in man.

R M Scott, J G Whitwam, M K Chakrabarti.   

Abstract

In seven normal subjects premedicated with atropine and pethidine and lightly anesthetized with thiopentone, the ventilatory response evoked by doxapram 20 mg i.v. was delayed on average from 15.7 s to 23.0 s when changing from air to oxygen breathing. Mean VE, immediately after the administration of doxapram was increased by 3.3 litre and 1.9 litre when breathing air and oxygen respectively. These findings indicate that doxapram has an effect on the peripheral chemoreceptors and are consistent with drug activity on both peripheral and central respiratory control mechanisms.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 911575     DOI: 10.1093/bja/49.3.227

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  5 in total

1.  Serum doxapram and respiratory neuromuscular drive in normal man.

Authors:  S Okubo; K Konno; T Ishizaki; T Suganuma; T Takubo; T Takizawa; M Tanaka
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 2.  Doxapram Treatment for Apnea of Prematurity: A Systematic Review.

Authors:  Roseanne J S Vliegenthart; Christine H Ten Hove; Wes Onland; Anton H L C van Kaam
Journal:  Neonatology       Date:  2016-10-20       Impact factor: 4.035

Review 3.  Treatment of apnea of prematurity.

Authors:  Varsha Bhatt-Mehta; Robert E Schumacher
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

4.  Effect of doxapram on control of breathing in cats.

Authors:  P Bopp; G Drummond; J Fisher; J Milic-Emili
Journal:  Can Anaesth Soc J       Date:  1979-05

5.  Doxapram hastens the recovery following total intravenous anesthesia with dexmedetomidine, propofol and remifentanil.

Authors:  Huan-Liang Wang; Shu-Hai Tang; Xue-Qin Wang; Wen-Hua Gong; Xiao-Mei Liu; Wei-Fu Lei
Journal:  Exp Ther Med       Date:  2015-02-02       Impact factor: 2.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.